chevron_leftBack
As of 24 April 2025, ADMA Biologics, Inc. has a market cap of $5.16B USD, ranking #2777 globally and #908 in the United States. It ranks #244 in the Healthcare sector, and #49 in the Biotechnology industry.
Key Stats
Market Cap
$5.16BUSD
Enterprise Value
$5.14BUSD
Revenue (TTM)
$426.45MUSD
EBITDA (TTM)
$147.03MUSD
Net Income (TTM)
$197.67MUSD
EBITDA Margin
34%
Profit Margin
46%
PE Ratio
26.8
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Adam Grossman
open_in_new
Employees
685
Founded
2004
Website
admabiologics.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 1.6% | 2.4% | 9.7% | 32% | 39% | 250% |
Upcoming Earnings
Earnings Date
Thu, May 8
Earnings Time
bedtime
After Close
EPS Estimate
$0.1400
75% yoy
Revenue Estimate
$116.4M
42% yoy
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
ADMA
ADMA Biologics Inc
ISIN: US0008991046
Shares Out.:
Shares Outstanding:
238.564M1
Shares Float:
230.227M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
21.73 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About ADMA Biologics, Inc.
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
